


[E-BOOK] Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation (Institute for Policy Innovation Books)

Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation (Institute for Policy Innovation Books)

Richard A. Epstein

*audiobook / *ebooks / Download PDF / ePub / DOC*



DOWNLOAD



READ ONLINE

#3092680 in Books 2008-12-02Original language:EnglishPDF # 1 9.20 x .70 x 6.10l, .95 #File Name: 0300143265296 pages | File size: 19.Mb

Richard A. Epstein : Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation (Institute for Policy Innovation Books) before purchasing it in order to gage whether or not it would be worth my time, and all praised Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation (Institute for Policy Innovation Books):

15 of 19 people found the following review helpful. Classic EpsteinBy CA Book ReaderThis is a great book that will make you think hard about how we regulate the pharmaceutical industry. You probably won't agree with everything but Epstein raises critical issues that need to be considered. If you are afraid of having your ideas being challenged (like the first reviewer) then don't order this book.

This book is the first to offer a comprehensive examination of the pharmaceutical industry by following the tortuous course of a new drug as it progresses from early development to final delivery. Richard A. Epstein looks closely at the regulatory framework that surrounds all aspects of making pharmaceutical products today, and he assesses which current legal and regulatory practices make sense and which have gone awry. While critics of pharmaceutical companies call for ever more stringent controls on virtually every aspect of drug development and approval, Epstein cautions that the effect of such an approach will be to stifle pharmaceutical innovation and slow the delivery of beneficial treatments to the patients who need them. The author considers an array of challenges that confront the industry--conflicts of interest among government, academe, and the drug companies; intellectual property rights that govern patents; FDA regulation; pricing disputes; marketing practices; and liability issues, including those brought to light in the recent VIOXX case. Epstein argues that to ensure the continuing creativity, efficiency, and success of the pharmaceutical industry, the best system will feature strong property rights and clearly enforceable contracts, with minimal regulatory and judicial interference.

In recent years, the pharmaceutical industry has come under often one-sided criticism from observers such as Marcia Angell. This book, while sure to be controversial, is in large part a healthy corrective to these works. Josh Lerner, author of *Innovation and Its Discontents*